About Us
We are a pioneering life science technology company dedicated to pushing the boundaries of single-cell and spatial technologies. Our mission is to empower our customers to break through technological barriers by providing cutting-edge single-cell and spatiotemporal omics solutions. We are committed to delivering novel and innovative solutions to meet the needs of our customers and help drive advancements in research discovery and applications towards disease diagnosis and treatment.
Our core team comprises scientists, technologists, and experts from top-tier universities and research institutions worldwide, with extensive experience in single-cell, spatiotemporal omics, and related life science technologies.
With M20 Seq technology, we have developed the world's first high-throughput full-length single-cell sequencing technology utilizing random primers. By leveraging this powerful technology in our VITA product line, we are providing innovative end-to-end solutions for single-cell transcriptome sequencing in various sample types. Additionally, our random primer-based M20 Spatial technology, alongside our innovative NATA spatial transcriptome product line, provides the first spatial full-transcriptome solution across various sample types. These advancements empower the discovery of secrets behind biological mechanisms and disease pathways.
View Website
Address:
1448 S Rolling Rd, Ste 218
Baltimore, MD 21227
USA
Contact:
Contact Form: Complete Omics Contact Page
View Website
Address:
38-123 CHS
650 Charles Young Dr.
Los Angeles, CA 90095
UCLA Mail Code 173517
USA
Contact:
Phone: +1 310-206-3945
Email: sequencing@mednet.ucla.edu
How We Get Here
Our mission is to break technological barriers and unravel the enigmas of life and disease origins using next-generation single-cell technologies, pioneering a new era of technological advancements in disease diagnosis and treatment.
Our main team members come from universities worldwide. We have long been engaged in the research and application of single-cell sequencing and related technologies and achieved globally-leading research and translational outcomes in respective areas.
- 2021.2
Company Establishment
- 2021.12
Angel Round Financing
By Qiming Venture Partners and Nest. Bio Capital - 2022.3
Product Launch
The world's first high-throughput single-bacterial transcriptome sequencing product - 2022.4
Pre-A Round Financing
By Sequoia Capital, Taiyu Investments, Qiming Venture Partners and Nest. Bio Capital - 2022.6
Pre-A+ Round Financing
By QiZhen Future Healthcare Fund - 2022.8
Product Launch
The world's first high-throughput single-cell full-length transcriptome sequencing product based on random primer principle - 2022.12
NGSC Ecosystem
In December 2022, partnered with multiple well-known brands to build a new generation single-cell (NGSC) technology ecosystem - 2023.5
NC Article Publication
The achievements of “M20 Seq”s FFPE single-cell high-throughput technology (also known as “snRandom seq”) were published on Nature Communications, making it the world's first SCI paper featuring FFPE single-cell research.
